MARKET

RLMD

RLMD

Relmada Therapeutics Inc
NASDAQ
4.240
+0.240
+6.00%
After Hours: 4.200 -0.04 -0.94% 18:34 12/05 EST
OPEN
4.030
PREV CLOSE
4.000
HIGH
4.310
LOW
3.990
VOLUME
637.30K
TURNOVER
--
52 WEEK HIGH
5.12
52 WEEK LOW
0.2404
MARKET CAP
310.93M
P/E (TTM)
-2.3595
1D
5D
1M
3M
1Y
5Y
1D
Relmada Therapeutics (RLMD) Price Target Increased by 900.00% to 10.20
NASDAQ · 20h ago
Relmada Therapeutics To Present 6-Month Follow-Up Data From Ongoing Phase 2 Study Of NDV-01 In Development For Non-Muscle Invasive Bladder Cancer, At SUO 2025
Benzinga · 3d ago
Relmada Therapeutics to present NDV-01 Phase 2 data at SUO meeting
TipRanks · 3d ago
Weekly Report: what happened at RLMD last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at RLMD last week (1117-1121)?
Weekly Report · 11/24 10:17
This Stock Is Up 704% in 2025 But Has No Products to Its Name
Barchart · 11/20 09:15
Relmada Therapeutics Raised to Outperform From Neutral by Mizuho
Dow Jones · 11/19 14:47
Relmada Therapeutics Price Target Raised to $10.00/Share From $1.00 by Mizuho
Dow Jones · 11/19 14:47
More
About RLMD
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.

Webull offers Relmada Therapeutics Inc stock information, including NASDAQ: RLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLMD stock methods without spending real money on the virtual paper trading platform.